Procarbazine (Matulane (US), Natulan (Canada), Indicarb (India) is an antineoplastic chemotherapy drug for the treatment of Hodgkin's lymphoma and certain brain cancers (such as Glioblastoma multiforme). It is a member of a group of medicines called alkylating agents. It gained FDA Approved in July 1969. The drug is metabolized and activated in the liver. It also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine.

Its mechanism of action is not fully understood. Metabolism yields azo-procarbazine and hydrogen peroxide^{[citation needed]} which results in the breaking of DNA strands.

When used to treat Hodgkin's Lymphoma, it is often delivered as part of the MOPP regimen that includes Mechlorethamine, Vincristine (tradename Oncovin), Prednisone, and Procarbazine. Alternatively, when used to treat certain brain tumors (malignant gliomas), it is often dosed as PCV when combined with Lomustine (often called CCNU) and Vincristine.

Procarbazine is also part of the more modern BEACOPP regimen used for Hodgkin's lymphoma.